Navigation Links
Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
Date:11/8/2012

SOUTH SAN FRANCISCO, Calif., Nov. 8, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Jefferies 2012 Global Healthcare Conference in London on Thursday, November 15th at 1:40 p.m. GMT.

To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with its partner AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase 2 clinical trials; and R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders.

Contact: Ryan Maynard   
Phone: 650.624.1284   
Email: invrel@rigel.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Rigel Announces Third Quarter 2012 Financial Results
2. Rigel to Present at UBS Global Life Sciences Conference
3. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
4. Rigel Announces Second Quarter 2012 Financial Results
5. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
6. Rigel Announces First Quarter 2012 Financial Results
7. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Isis Pharmaceuticals To Present At The 2012 Credit Suisse Healthcare Conference
9. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
10. VisionCare Implantable Telescope Technology Presentations Featured at Upcoming American Academy of Ophthalmology and Ophthalmology Innovation Summit Meetings
11. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ... body composition, including reductions in body fat content ...
(Date:1/14/2014)... BEVERLY HILLS, Calif. , Jan. 14, 2014 ... , offers Los Angeles a premier ... Duality laser and a $99 treatment special. Dr. Brandeis, focus ... medical technology and offering expert medical advice to all patients. ... a dramatic increase in the presence of tattoo regret and ...
(Date:1/14/2014)... 2014 NineSigma , Inc., the leading ... Innovation Leadership Summit , May 14-16, 2014 at the ... Ohio . This is the ... to breakthrough achievements through open innovation. Participants will learn ... across disciplines and even across industries. ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... NUTLEY, N.J., Jan. 14 Following an ... of PEGASYS(R),(peginterferon alfa-2a) in combination with ribavirin ... C, in the United States and globally.,Despite ... "IDEAL" study that potentially,favored patients taking Peg-Intron(TM) ...
... - MAA submission based on data from largest Phase 3 study conducted ... overall survival advantage compared to conventional ... compared to 26.2% for ... conventional care regimens, BOULDER, Colo., Jan. 14 Pharmion ...
Cached Medicine Technology:Roche responds to announcement of 'IDEAL' hepatitis C trial results 2Roche responds to announcement of 'IDEAL' hepatitis C trial results 3Roche responds to announcement of 'IDEAL' hepatitis C trial results 4Roche responds to announcement of 'IDEAL' hepatitis C trial results 5Roche responds to announcement of 'IDEAL' hepatitis C trial results 6Roche responds to announcement of 'IDEAL' hepatitis C trial results 7Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 2Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 3Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 4Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 5Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 6Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 7
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Morning Show On 101.9fm THE MIX/WTMX ... Will Be Event Host and Emcee, GURNEE, Ill., Oct. 2 ... one local boy, Jake Robert Widman, of Gurnee, won,t be,blowing out the ... of pediatric cancer called neuroblastoma on May 27, 2005, when he was,just ...
... and treatment of low-back pain has prompted the American ... (ACP) to issue a new treatment guideline. The guideline ... conducted by investigators at the Oregon Evidence-Based Practice Center ... recommendations issued by a panel of experts convened by ...
... to sudden cardiac death , TUESDAY, Oct. 2 ... perindopril, along with a beta blocker, may help ... Marfan syndrome, research shows. , Marfan syndrome, which ... excessive bone elongation and joint flexibility, and eye ...
... Calif., Oct. 2 Angel Flight West (AFW),awarded The ... at,AFW,s 24th Anniversary Awards on Saturday, September 29. Dr. ... year. As an AFW,pilot, he flies people in need ... and from medical facilities. Dr. Irish, like,all AFW volunteer ...
... gamma imaging for both ... NEWPORT NEWS, Va., Oct. 2 Recently published ... Gamma Imaging,(BSGI) may be more specific than MRI ... compiled by Dr. Rachel Brem and,colleagues at The ...
... 2 Aflac today announced,that Jeffrey M. Herbert ... officer of the company,s U.S. insurance operation. Herbert ... for his departure from the,company. (Logo: ... Aflac president and chief,operating officer for Aflac U.S., ...
Cached Medicine News:Health News:Super Jake Foundation Hosts 3rd Annual 'Heroes Bash' on Nov. 3 to Benefit Pediatric Cancer Research 2Health News:Super Jake Foundation Hosts 3rd Annual 'Heroes Bash' on Nov. 3 to Benefit Pediatric Cancer Research 3Health News:New clinical guideline for low-back pain 2Health News:New clinical guideline for low-back pain 3Health News:Drug Combo Helps Fight Marfan Syndrome 2Health News:Angel Flight West Recognizes Colorado Pilots and Supporters at AFW 24th Anniversary Awards 2Health News:Study Determines Breast-Specific Gamma Imaging Has Higher Specificity Than MRI in Patients With Equivocal Mammograms 2Health News:Study Determines Breast-Specific Gamma Imaging Has Higher Specificity Than MRI in Patients With Equivocal Mammograms 3Health News:Aflac Announces Resignation of U.S. Marketing Officer 2Health News:Aflac Announces Resignation of U.S. Marketing Officer 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: